Herceptin

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• The human epidermal growth factor receptor-2 (HER2) is a validated target for cancer therapy.
• Herceptin is a monoclonal antibody approved for HER2-positive breast cancer treatment, used in over 150,000 women.
• Understanding the developmental history of Herceptin offers insights into targeted drug discovery.

Observation:

• The specific developmental history, critical decision points, and rationale for pursuing a monoclonal antibody approach for HER2 have not been fully documented.
• This review aims to elucidate these pivotal events and decisions.
• The development of Herceptin represents a significant milestone in targeted cancer therapeutics.

Findings:

• The review details the critical events and decision-making processes that led to the development of Herceptin.
• It explains the strategic choices made during the drug discovery and development program.
• Herceptin emerged as the first therapeutic agent successfully targeting tyrosine kinases in cancer.

Implications:

• Sharing the Herceptin development experience can inform future drug discovery and development processes.
• The success of Herceptin provides a model for developing targeted therapies against other HER family members.
• New therapeutic strategies and future directions for targeting the HER family are discussed.